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Abstract
Introduction: Septic shock is characterized by altered tissue perfusion associated with persistent arterial
hypotension. Vasopressor therapy is generally required to restore organ perfusion but the optimal mean arterial
pressure (MAP) that should be targeted is uncertain. The aim of this study was to assess the effects of increasing
MAP using norepinephrine (NE) on hemodynamic and metabolic variables and on microvascular reactivity in
patients with septic shock.
Methods: This was a single center, prospective, interventional study conducted in the medico-surgical intensive
care unit of a university hospital. Thirteen patients in septic shock for less than 48 hours who required NE
administration were included. NE doses were adjusted to obtain MAPs of 65, 75, 85 and (back to) 65 mmHg. In
addition to hemodynamic and metabolic variables, we measured thenar muscle oxygen saturation (StO2), using
near infrared spectroscopy (NIRS), with serial vaso-occlusive tests (VOTs) on the upper arm. We also evaluated the
sublingual microcirculation using sidestream dark field (SDF) imaging in 6 of the patients.
Results: Increasing NE dose was associated with an increase in cardiac output (from 6.1 to 6.7 l/min, P<0.05) and
mixed venous oxygen saturation (SvO2, from 70.6 to 75.9%, P<0.05). Oxygen consumption (VO2) remained stable,
but blood lactate levels decreased. There was a significant increase in the ascending slope of StO2 (from 111 to
177%/min, P<0.05) after VOTs. SDF imaging showed an increase in perfused vessel density (PVD, from 11.0 to 13.2
n/mm, P<0.05) and in microvascular flow index (MFI, from 2.4 to 2.9, P<0.05).
Conclusions: In this series of patients with septic shock, increasing MAP above 65 mmHg with NE was associated
with increased cardiac output, improved microvascular function, and decreased blood lactate concentrations. The
microvascular response varied among patients suggesting that individualization of blood pressure targets may be
warranted.
Introduction
Septic shock is characterized by an alteration in tissue
perfusion associated with persistent arterial hypotension
- generally defined as a systolic arterial pressure of less
than 90 mm Hg [1] - despite adequate fluid resuscita-
tion [2]. This leads to organ dysfunction and even death
in around 50% of cases [3]. Evaluation of systemic
hemodynamic variables can be inadequate to identify
tissue perfusion, which is directly influenced by addi-
tional microvascular factors. De Backer and colleagues
[4] showed that sepsis is associated with reduced
microvascular density, an increased number of non-per-
fused small vessels, and heterogeneity among microcir-
culatory areas. There are several possible reasons for
these abnormalities, including the release of mediators
and cytotoxic substances - such as free oxygen radicals,
various cytokines, and prostanoids - which can alter
endothelial function and cell deformability, induce vas-
cular hyporeactivity to catecholamines [5], induce coa-
gulation abnormalities [6], increase cell adhesion to
endothelial cells, and induce interstitial edema. Because
of its vasoactive effects, norepinephrine (NE) could con-
tribute to alter the microcirculation and impair cellular
metabolism.
In septic shock, fluid resuscitation is insufficient to
restore hemodynamic stability, so that vasopressor
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Recommendations suggest that a mean arterial pressure
(MAP) of around 65 mm Hg should initially be targeted
[1]. There is some suggestion that an MAP below this
value may be associated with a worse evolution [7]. An
arterial pressure that is too low induces a loss of autore-
gulation of organ flow, so that tissue perfusion becomes
directly dependent on the arterial pressure level. How-
ever, whether a higher MAP should be targeted is a
matter of debate. Ledoux and colleagues [8] showed that
i n c r e a s i n gM A Pf r o m6 5t o7 5a n dt o8 5m mH gd i d
not influence urinary output, blood lactate levels, or gas-
tric intramucosal partial pressure of carbon dioxide
(PCO2) in 10 patients with septic shock. Bourgoin and
colleagues [9] observed that increasing MAP from 65 to
85 mm Hg did not modify creatinine clearance or blood
lactate level. However, Deruddre and colleagues [10]
showed that, although renal perfusion evaluated by Dop-
pler ultrasonography did not change overall when MAP
was increased above 65 mm Hg, individual response was
highly variable and several patients did have a marked
increase in renal perfusion. Jhanji and colleagues [11]
showed that increasing MAP from 60 to 70, 80, and 90
mm Hg by increasing the NE dose could increase oxy-
gen delivery (DO2) and cutaneous microvascular flow;
however, the authors found no significant effect on the
microcirculation when using sidestream dark field (SDF)
imaging techniques. Using the same SDF imaging tech-
niques and a similar protocol with MAP at 65, 75, and
85 mm Hg, Dubin and colleagues [12] reported no
change in the sublingual microcirculation. All of these
data suggest that considerable interpatient variability
can occur and that the optimal MAP level remains
unclear.
Because of these unsettled controversies, we studied
the hemodynamic, metabolic, and microcirculatory
effects of an increase in NE dose in patients with septic
shock. Our hypothesis was that increasing MAP by
increasing NE doses would improve microvascular func-
tion in patients with septic shock.
Materials and methods
This was a single-center study conducted over a 1-year
period and approved by the local ethics committee of
Erasme University Hospital (Brussels, Belgium).
Informed consent was obtained from all patients or
their closest relative.
Patients
We studied 13 adult patients who had had septic shock
for less than 48 hours. All patients had an arterial cathe-
ter, a central venous catheter, and a pulmonary artery
catheter (Swan-Ganz) in place. All patients required an
NE infusion for arterial hypotension resistant to fluid
therapy, supported by a change in pulse pressure (ΔPP)
of less than 13% [13]. All patients were treated with
mechanical ventilation and received an infusion of mida-
zolam for sedation and morphine for analgesia. Inotro-
pic support was provided with dobutamine when judged
necessary by the attending physician. The patients were
all stabilized and had undergone initial resuscitation.
Exclusion criteria were need for an MAP of higher than
65 mm Hg (for example, severe head trauma, recent
stroke, or advanced arteriopathy), Child-Pugh C cirrho-
sis, scleroderma or drepanocytosis, significant arrhyth-
mias, pregnancy, or refusal to participate in the study.
Protocol
NE doses were adjusted to maintain a baseline MAP of
65 ± 2 mm Hg. After stabilization, basal measurements
were performed twice, 15 minutes apart (’baseline 1 and
2’), and the NE doses were increased to obtain an MAP
of 75 ± 2 mm Hg; patients were allowed to stabilize for
30 minutes before taking measurements (’increasing 1’).
NE doses were then increased to reach an MAP of 85 ±
2m mH gw i t h i n1 5m i n u t e s ,a n dt h em e a s u r e m e n t s
were repeated after another 30-minute stabilization per-
iod (’increasing 2’). NE doses were then decreased to
return to an MAP of 65 ± 2 mm Hg, and another stabi-
lization period of 30 minutes was allowed before the
final measurements (’baseline 3’). During the protocol,
no other change in treatment was allowed.
Measurements
We measured temperature, heart rate, cardiac output,
systemic and pulmonary arterial pressures, central
venous pressure (CVP), pulmonary artery occlusion
pressure, and ΔPP. Arterial and venous gases were
obtained to determine pH, arterial partial pressure of
carbon dioxide (PaCO2), arterial partial pressure of oxy-
gen (PaO2), hemoglobin concentration, arterial hemo-
globin saturation (SaO2), mixed venous hemoglobin
saturation (SvO2), and blood lactate concentration. Vas-
cular resistances were calculated by standard formulas.
The Acute Physiology and Chronic Health Evaluation II
(APACHE II) score [14] and the Sequential Organ Fail-
ure Assessment (SOFA) score [15] were calculated.
In each patient, we used near-infrared spectroscopy
(NIRS) (InSpectra™ Model 650; Hutchinson Technology
Inc., Hutchinson, MN, USA) [16,17] to evaluate tissue
oxygenation non-invasively by using the differences in
absorption of near-infrared light by oxyhemoglobin and
deoxyhemoglobin. The NIRS probe was placed on the
thenar eminence to measure tissue hemoglobin oxygen
saturation (StO2). A vascular occlusion test (VOT) [18]
was used to measure different variables reflecting local
metabolic demand and microcirculatory function. The
VOT was performed by inflating a pneumatic cuff
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pressure for 3 minutes to follow the evolution of StO2
and global tissue hemoglobin (THI). The descending
slope of the StO2 and the nirVO2I (the reverse descend-
ing slope multiplied by the average THI during the first
occlusion minute) [19] estimate regional tissue oxygen
consumption (VO2). The ascending slope of the StO2
and the reactive hyperemia reflect microcirculatory reac-
tivity (that is, the vessels’ capacity to adjust oxygen
extraction).
In six patients, we also assessed the sublingual micro-
circulation using the SDF imaging technique [20]
(Microscan, Microvision Medical, Amsterdam, The
Netherlands), in which a green light is reflected by the
background and absorbed by hemoglobin in red blood
cells flowing in superficial vessels. These six patients
had the same characteristics as the others. We based
our analysis on previously established criteria for micro-
circulatory perfusion [21] by obtaining 20-second video
clips of five different sites by a device with a × 5 objec-
tive lens. The data were analyzed blindly and randomly.
Using a cutoff diameter of 20 μm, we separated the ves-
sels into two categories: small (corresponding to capil-
laries) and large (corresponding to venules). We also
determined two perfusion indices: the microvascular
flow index (MFI) and the vessel density. The MFI char-
acterizes microvascular flow as absent (0), intermittent
(1), sluggish (2), or normal (3). The functional capillary
density (FCD) is estimated by the measurement of per-
fused vessel density (PVD) (that is, the proportion of
perfused vessels, multiplied by vessel density).
Statistical analysis
Data were analyzed using SPSS 13.0 for Windows
(SPSS Inc., Chicago, IL, USA). Descriptive statistics
were computed for all study variables. To verify the
normality of the distributions of continuous variables,
histograms and normal quantile plots were examined
and the Kolmogorov-Smirnov test was used. Continu-
ous variables are presented as mean (95% confidence
intervals) if normally distributed and as median (25%
to 75% interquartile range) if not normally distributed.
Categorical variables are presented as number and per-
centage. To analyze the time courses of the hemody-
namic, metabolic, or NIRS parameters, we used
analysis of variance for repeated measurement followed
by paired t test or Friedman test followed by the Wil-
coxon test. To correct for multiple comparison, a Bon-
ferroni correction was used. All statistics were two-
tailed, and a P value of less than 0.05 was considered
to be significant. After checking that there was no sig-
nificant difference between the first two baseline mea-
surements, we averaged them to obtain only one
baseline.
Results
Clinical data of the 13 patients are presented in Table 1.
The most common source of sepsis was abdominal
infection. The mean duration of shock prior to study
inclusion was 24.1 ± 14.7 hours. Our patients had
already undergone initial resuscitation and had been in
shock for an average of 24 hours. Three patients
received dobutamine (4 μg/minute). The mean baseline
CVP was 12 mm Hg, cardiac index was 3.6 L/minute-
m², SvO2 was 70%, and ΔP Pw a sl e s st h a n1 3 %( T a b l e
2). NE doses during the study are shown in Table 2.
There were no adverse effects associated with the
increasing NE doses.
Hemodynamic and metabolic variables
Cardiac output increased from 6.1 L/minute (5.4 to 6.8
L/minute) at baseline to 6.7 L/minute (5.9 to 7.6 L/min-
ute) at an MAP of 85 mm Hg (P <0.05) without signifi-
cant changes in heart rate (Tables 2 and 3). Systemic
vascular resistance also increased. SvO2 increased from
70.6% (67.9% to 73.2%) to 75.9% (71.7% to 80.1%) (P
<0.05). DO2 increased but VO2 remained stable. Blood
lactate concentrations decreased.
Near-infrared spectroscopy variables
The ascending slope increased from 110.6%/minute
(80.0 to 141.2%/minute) at baseline to 176.9%/minute
(121.6 to 232.2%/minute) at 85 mm Hg (Figure 1)
(Table 4). There was no significant change in the des-
cending slope or in the nirVO2I.
Table 1 Clinical data
Parameter Value
Age in years, mean (95% CI) 63.3 (55.0-71.6)
Males/females 9/4
Weight in kilograms, mean (95% CI) 80 (69-91)
Body mass index, mean (95% CI) 27.3 (22.6-32.0)
APACHE II score, mean (95% CI) 22.7 (18.9-26.5)
SOFA score, mean (95% CI) 12.8 (11.4-14.2)
Source of infection, number (percentage)
Abdominal 6 (46)
Lung 5 (39)
Unknown 2 (15)
Comorbidities, number (percentage)
Chronic hypertension 8 (62)
Diabetes 5 (38)
Chronic renal failure 2 (15)
ICU length of stay in days, median (25-75% IQR) 17 (6-27)
28-day mortality, number (percentage) 2 (17)
APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive
care unit; SOFA, Sequential Organ Failure Assessment; CI: confidence interval;
IQR: interquartile range
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There was considerable interindividual variability in the
proportion of small perfused vessels (Figure 2 and Table
4). Global PVD showed a significant increase from 11.0
vessels per millimeter (8.6 to 13.3 vessels per millimeter)
to 13.2 vessels per millimeter (11.9 to 14.5 vessels per
millimeter), but the differences were not significant for
small vessels. The MFI showed variable values between
patients but was mainly sluggish at baseline (2.4, 2.2 to
2.7) and increased significantly toward a normal flow
(2.9, 2.8 to 2.9) when MAP increased to higher levels
(Figure 3).
Discussion
The major finding of this study was that increasing
M A Pf r o m6 5t o7 5a n d8 5m mH gb yt i t r a t i n gN E
doses was associated with an increase in cardiac output,
a decrease in blood lactate level, and an improvement in
microcirculatory function as evaluated by NIRS. The
study of the microcirculation by SDF in six patients
showed some improvements characterized by an
increase in perfused vessel density and a normalization
of blood flow in these vessels.
Our patients had already undergone initial resuscita-
tion and had been in shock for an average of 24 hours.
To ensure that alterations in the variables were not
influenced by factors other than the MAP increase asso-
ciated with NE, no other changes in treatment were
allowed during the study period. Moreover, there was
no temperature change during the short observation
period. To rule out the possible influence of the natural
course of the shock, one last measurement was made
when the MAP had returned to the baseline level of 65
mm Hg.
N Ei sac o m m o n l yu s e dv a s o p r e s s o ra g e n ti ns e p t i c
shock. Its strong alpha-adrenergic properties make it a
very effective vasopressor agent [22], and it is now con-
sidered the vasopressor of choice [23]. Nevertheless,
questions arise as to whether this vasoconstriction is not
deleterious for the microcirculation. Increasing the
doses of NE was associated with increases in cardiac
output, DO2, and SvO2. Interestingly, in this situation of
sepsis, which is characterized by relative cardiac depres-
sion, the increase in cardiac output could be explained
by the beta-1 adrenergic action of NE. Although there
was no significant increase in VO2 in our study, blood
lactate concentrations decreased slightly. This suggests
that tissue blood flow and oxygen supply were increased
without modification of global VO2. Vessel blood flow
depends on, among other factors, the diameter of the
vessel and the applied pressure gradient. The vasocon-
stricting effects of NE were manifest by a significant
Table 2 Norepinephrine doses and hemodynamic variables
65 mm Hg 75 mm Hg 85 mm Hg 65 mm Hg
Norepinephrine, μg/minute 17.3 (5.9-28.6) 24.5 (9.5-39.5)
a 32.7 (14.0-51.4)
a 22.4 (11.0-33.8)
Mean arterial pressure, mm Hg 66.0 (65.1-66.8) 75.9 (73.5-78.3)
a 86.3 (84.3-88.4)
a 66.2 (65.1-67.3)
Heart rate, beats per minute 93.5 (83.9-103.1) 91.4 (81.4-101.5) 92.8 (82.1-103.6) 94.2 (81.7-106.7)
Cardiac output, liters per minute 6.1 (5.4-6.8) 6.5 (5.7-7.3) 6.7 (5.9-7.6)
a 6.1 (5.4-6.8)
Mean pulmonary arterial pressure, mm Hg 29 (24.9-33.1) 30.3 (26-34.7) 32.2 (27.9-36.5)
a 29.4 (24.8-34.0)
Pulmonary artery occlusion pressure, mm Hg 15.3 (12.7-18) 15.4 (12.7-18.2) 16.1 (13.5-18.6) 14.6 (12.2-17.1)
Central venous pressure, mm Hg 12.0 (9.8-14.3) 12.8 (10.3-15.2) 13.4 (11.1-15.7)
a 12.4 (10.3-14.5)
Systemic vascular resistance, dyne/second per cm
−5 716 (647-786) 803 (711-896)
a 902 (793-1,010)
a 726 (645-806)
Pulmonary vascular resistance, dyne/second per cm
−5 181 (141-222) 188 (141-234) 197 (150-244) 184 (134-234)
Change in pulse pressure, percentage 2 (1.5-4.5) 2.5 (1-8) 1.5 (0-4) 4 (3-7)
aP <0.05 versus baseline.
Table 3 Metabolic variables
65 mm Hg 75 mm Hg 85 mm Hg 65 mm Hg
Hemoglobin, g/dL 8.9 (8.0-9.7) 9 (8.2-9.9) 8.9 (7.9-10.0) 8.8 (7.8-9.8)
Temperature, °C 37.3 (36.5-38.0) 37.3 (36.5-38.1) 37.3 (36.6-38.1) 37.4 (36.6-38.2)
Lactate, mEq/L 2.3 (1.5-3.1) 2.2 (1.4-2.9)
a 2.1 (1.4-2.8)
a 2.2 (1.5-3.0)
SaO2, percentage 97.2 (96.4-98.1) 97.5 (96.7-98.3) 97.9 (96.9-98.9) 97.8 (96.9-98.7)
SvO2, percentage 70.6 (67.9-73.2) 72.3 (69.3-75.3) 75.9 (71.7-80.1)
a 69.0 (65.8-72.2)
DO2, mL/minute 728 (633-824) 806 (678-933) 826 (687-965)
a 721 (623-819)
VO2, mL/minute 197 (175-220) 203 (173-232) 177 (149-204) 208 (179-238)
EO2, mL/minute 27.5 (24.6-30.4) 25.8 (22.6-29.0) 22.5 (18.3-26.7)
a 29.4 (26.1-32.7)
aP <0.05 versus baseline. DO2, oxygen delivery; EO2, oxygen extraction ratio; SaO2, arterial hemoglobin saturation; SvO2, mixed venous oxygen saturation; VO2,
oxygen consumption.
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increase in cardiac output may have contributed to the
increased microvascular flow observed in our study.
The microvascular changes were modified in parallel
with an increase in cardiac output and in systemic vas-
cular resistance. As all variables move in the same direc-
tion, we can hypothesize that both these variables were
involved in the modifications but there were no correla-
tions between the changes in the ascending slope and
the increase in cardiac output or in systemic vascular
resistance. As this is probably a situation of loss of
arterial pressure autoregulation, regional microvascular
changes (like recruitment) may partly explain the signifi-
cant differences.
Microcirculatory alterations have been demonstrated
in sepsis [4] and are particularly marked in non-survi-
vors [18,24], improving in those patients who survive
but persisting in patients who develop organ failure.
These microvascular alterations are largely related to
endothelial cell dysfunction and loss of the ability to
regulate vascular tone [25]. The study of vascular reac-
tivity with NIRS - using the occlusive test - provides an
estimation of microvessel function [18]. This hypoxic
stimulus promotes the ‘recruitment’, namely the
Figure 1 Ascending slope in individual patients. There was a systematic response of the slope to the increase in mean arterial pressure.
Table 4 Near-infrared spectroscopy and sidestream dark field variables
65 mm Hg 75 mm Hg 85 mm Hg 65 mm Hg
NIRS variables
StO2 baseline, percentage 82.5 (79.0-85.9) 81.0 (77.0-85.0) 81.2 (77.6-84.7) 77.8 (73.6-82.1)
Descending slope, percentage/minute −14.8 (−18.0 - −11.6) −14.5 (−18.9 - −10.0) −16.4 (−22.0 - −10.9) −15.7 (−21.9 - −9.4)
nirVO2I, arbitrary units 139 (114-165) 122 (98-146) 153 (109-196) 129 (93-165)
Delta StO2, percentage 7.4 (5.3-9.5) 8.4 (5.2-11.6) 7.7 (5.4-9.9) 7.4 (5-9.7)
AUC ratio, percentage 0.11 (0.05-0.16) 0.12 (0.09-0.15) 0.10 (0.08-0.14) 0.10 (0.07-0.15)
Ascending slope, percentage/minute 111 (80-141) 172 (115-228)
a 177 (122-232)
a 114 (94-134)
SDF variables
Total vessel density 12.8 (10.5-15.0) 13.2 (11.1-15.3) 14.3 (12.9-15.7) 13.7 (11.0-16.4)
Small vessel density 10.7 (8.5-12.9) 11 (8.5-13.4) 11.6 (10.1-13.1) 11.7 (9.0-14.3)
PVD, vessels/mm 11.0 (8.6-13.3) 12.0 (9.4-14.5) 13.2 (11.9-14.5)
a 12.1 (9.2-14.9)
Small PVD, vessels/mm 9.1 (6.4-11.9) 9.8 (6.9-12.8) 10.7 (9.0-12.3) 10.3 (7.1-13.5)
All PPV, percentage 85.9 (80.1-91.6) 89.5 (83.7-95.2) 92.6 (89.9-95.3) 87.7 (79.9-95.6)
Large PPV, percentage 95.5 (93.6-97.4) 95.4 (88.8-102.0) 97.5 (95.2-99.7) 89.8 (82.7-96.9)
Small PPV, percentage 83.6 (76.1-91.0) 87.9 (81.8-94.0) 91.1 (87.9-94.3) 86.4 (76.3-96.5)
Microvascular flow index 2.4 (2.2-2.7) 2.7 (2.4-2.9) 2.9 (2.8-2.9)
a 2.5 (2.2-2.9)
aP <0.05 versus baseline. AUC, area under the curve; NIRS, near-infrared spectroscopy; nirVO2I, reverse descending slope multiplied by the average tissue
hemoglobin index during the first occlusion minute; PPV, proportion of perfused vessels; PVD, perfused vessel density; SDF, sidestream dark field; StO2, thenar
muscle oxygen saturation.
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called ‘reactive hyperemia’. With NIRS, impairment in
tissue reperfusion after hypoxia in the thenar eminence
has been shown to be correlated with the severity of
sepsis and with outcome [18].
StO2 was not affected by the different arterial pressure
levels and remained lower than in a healthy population
[19]. The absence of changes in StO2 suggests that
NIRS changes were not the consequence of the increase
in cardiac output. The ascending slope of the StO2,t h e
delta between StO2 at baseline and at the hyperemia
peak, and the ratio between the two areas under the
curves can be used to estimate capillary reactivity. In
our study, although delta StO2 and the ratio between
the areas under the curves did not change, the StO2
reperfusion slope increased when the arterial pressure
was increased by NE, indicating some improvement in
microvascular reactivity. To compare our variables with
values found in other NIRS studies during sepsis, we
can express the StO2 recovery slope results in percen-
tage per second [18,19]. The ascending slope at baseline
was around 1.9%/second, which is markedly altered and
corresponds to values observed in septic shock [19].
When MAP was increased to 85 mm Hg, the ascending
slope increased to 3.1%/second, a value seen in healthy
volunteers. In Figure 1, we can see variability in the
reperfusion slope, indicating that some patients derived
greater benefit from this intervention than did others.
T h et i s s u eV O 2 can be estimated from either the des-
cending StO2 s l o p e-w h i c hs h o w st h er a t eo ft i s s u e
VO2 a tt h eo n s e to fh y p o x i a-o rt h en i r V O 2I[ 1 9 ] ,
which corresponds to a decrease in StO2 during the first
minute of hypoxia weighted by the conversion rate of
oxyhemoglobin into deoxyhemoglobin during this per-
iod. None of these variables changed, indicating that
increasing NE dose has no effect on the local tissue
VO2 despite the microvascular recruiting reflected by
the rise in StO2.
Our study also showed an improvement in microvas-
cular reactivity, evaluated by NIRS, related to the
changes in arterial pressure during sepsis. As expected,
there was some interpatient variability. Our data are in
line with the observation that correction of severe hypo-
tension (MAP of less than 65 mm Hg) by NE adminis-
tration in patients with septic shock resulted in
improvement in microvascular reactivity measured by
NIRS [26]. It is, of course, difficult to totally rule out a
pharmacologic effect of NE on the ascending slope but
the concordant changes in sublingual microcirculation
suggest that it was related to improved microvascular
perfusion.
We also used SDF techniques to study the sublingual
microcirculation in 6 of the 13 patients. There was an
increase in the proportion of all perfused vessels and of
perfused small vessels. The changes were not significant,
but these parameters evolved from abnormal values at
baseline - as expected in patients with sepsis - to almost
normal values when the MAP was increased to 85 mm
Hg. Almost all large vessels were perfused, and this is
expected when the probe is properly applied without
too much local pressure (thisi sa c t u a l l yaq u a l i t yc o n -
trol measure). Although the changes in small PVD were
not significant, there was a significant increase in the
global PVD (that is, some improvement in FCD), which
probably can be explained by the increase in the propor-
tion of small perfused vessels. Finally, the MFI showed
variable values between patients but was mainly sluggish
at baseline and increased toward a normal flow at higher
MAP values. Accordingly, increasing arterial pressure
a b o v e6 5m mH gi ns e p t i cs h o c km a yh a v eb e n e f i c i a l
effects on perfusion and flow in the microvessels in
patients with septic shock.
Figure 2 Proportion of small perfused vessels in individual
patients.
Figure 3 Microvascular flow index. Data are presented as median
(interquartile range). *Significant difference at 5% level (Bonferroni
correction) versus baseline.
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[8,9,11], but several factors may explain these differ-
ences. For example, Ledoux and colleagues [8] used
dopamine in addition to NE, and the use of a second
vasoactive agent may have influenced the vascular reac-
tivity. Bourgoin and colleagues [9] observed significant
increases in cardiac index, SvO2, and DO2 but no signif-
icant changes in renal perfusion. It should be noted that
their period of observation was quite long. Moreover,
these data are in contradiction to the work of Deruddre
and colleagues [10], who reported a significant increase
in urinary output in a shorter study period. Two other
studies [11,12] used SDF to assess microcirculatory
changes after increasing MAP by NE during sepsis and
found no significant changes in microcirculatory vari-
ables. The apparent differences between these studies
and the present study may be related to differences in
fluid repletion or in the timing of the study or both. In
the study by Jhanji and colleagues [11], three patients
needed fluid administration, suggesting that resuscita-
tion may not have been complete. Moreover, the inclu-
sion time varied from 12 hours to 3.5 days after the
onset of septic shock, likely with different microcircula-
tion reactivity among patients. Finally, patient selection
can also represent an important explanation for the dif-
ferences with the study of Dubin and colleagues [12], in
which an important variability in the response was
observed among the patients, some of whom presented
an improvement in microvascular perfusion during the
increase in NE dosage.
Our study has several limitations. First, we included a
relatively small number of patients, as did other studies
[8-12], and had strict enrollment criteria. We excluded
those who died early despite initial resuscitation attempts
and those who could not be stabilized, and patients with
notable comorbidities (like cirrhosis, arteriopathy, or
impaired cardiac function) were also excluded. Moreover,
our patients all had normal or high cardiac output.
Therefore, extrapolation of our results to all patients in
septic shock and notably unstable patients or those with
hypodynamic shock may be problematic. In addition, the
SDF measurements were not performed on all patients.
Second, we did not include a control group. However,
t h ep a t i e n t sw e r eu s e da st h e i ro w nc o n t r o l ,a sw e
obtained measurements before and after manipulation of
blood pressure. Since there was no difference between
the final measurements and the first baseline level, we
can exclude an influence of spontaneous changes over
time. Finally, this study investigated only immediate
changes to the increase in arterial pressure caused by
increased doses of NE. To extrapolate the impact of
these changes to periods in which the MAP is maintained
above 65 mm Hg for longer would be difficult, namely
because of the likely influence of concurrent events.
More fundamentally, interindividual differences are likely
so that having an identical MAP target for all patients is
probably naïve. In addition, these data cannot be extrapo-
lated to other vasopressor agents, and although we
observed no adverse effects associated with the increasing
dose of NE in our study, higher doses of NE over longer
periods may be associated with a greater risk of potential
adverse events, including arrhythmias.
Conclusions
In the treatment of patients in septic shock, increasing
MAP above 65 mm Hg with higher doses of NE can
result in increased cardiac output, improved microcircu-
latory function, and decreased lactate concentrations.
The present observations challenge the commonly heard
statement that an MAP of 65 to 70 mm Hg is adequate
for most patients with septic shock and suggest that
microvascular studies may be helpful to define the opti-
mal target in a given individual. The microvascular
response is variable between patients and suggests that
personal adaptation of the MAP is needed. Additional
studies should be carried out to develop criteria for
determining an individually adapted arterial pressure
threshold and to evaluate the long-term effects of this
strategy.
Key messages
￿ Increasing mean arterial pressure by norepinephr-
ine during septic shock can increase cardiac output
and improve microvascular flow and reactivity in
stable resuscitated patients without modification of
global oxygen consumption.
￿ There is considerable interindividual variability in
microvascular response, suggesting that the level of
mean arterial pressure should be adapted to each
patient.
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